Hutchinson Capital Management Abb Vie Inc. Transaction History

Hutchinson Capital Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$154.79 - $180.76 $4,334 - $5,061	-28 Reduced 2.08%	1,317 $225,000
Q1 2024 May 06, 2024	BUY	$159.82 - $182.1 $3,196 - $3,642	20 Added 1.51%	1,345 $244,000
Q4 2023 Feb 07, 2024	SELL	$137.6 - $154.97 $3,990 - $4,494	-29 Reduced 2.14%	1,325 $205,000
Q3 2023 Nov 09, 2023	BUY	$133.59 - $154.65 $180,880 - $209,396	1,354 New	1,354 $201,000
Q1 2023 May 04, 2023	BUY	$144.61 - $166.54 $289 - $333	2 Added 0.16%	1,257 $200,000
Q4 2022 Feb 13, 2023	BUY	$138.31 - $165.87 $173,579 - $208,166	1,255 New	1,255 $202,000
Q1 2022 May 11, 2022	SELL	$131.98 - $163.75 $196,122 - $243,332	-1,486 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $159,640 - $201,991	1,486 New	1,486 $201,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Hutchinson Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hutchinson Capital Management with notifications on news.